Cargando…
Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 “optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)”
Opioid use disorder continues to be a significant problem in the United States and worldwide. Three medications—methadone, buprenorphine, and extended-release injectable naltrexone,— are efficacious for treating opioid use disorder (OUD). However, the utility of these medications is limited, in part...
Autores principales: | Shulman, Matisyahu, Weiss, Roger, Rotrosen, John, Novo, Patricia, Costello, Elizabeth, Nunes, Edward V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7936466/ https://www.ncbi.nlm.nih.gov/pubmed/33676577 http://dx.doi.org/10.1186/s13722-021-00223-z |
Ejemplares similares
-
Collaborative care programs for pregnant and postpartum individuals with opioid use disorder: Organizational characteristics of sites participating in the NIDA CTN0080 MOMs study
por: Kropp, Frankie B., et al.
Publicado: (2023) -
The disease-specific clinical trial network for primary ciliary dyskinesia: PCD-CTN
por: Raidt, Johanna, et al.
Publicado: (2022) -
Time-lagged association between counseling and/or 12-Step attendance with subsequent opioid use in a secondary analysis from a randomized, clinical trial of medications for opioid use disorder
por: Hefner, Kathryn, et al.
Publicado: (2022) -
The NIDA clinical trials network: evolving, expanding, and addressing the opioid epidemic
por: Tai, Betty, et al.
Publicado: (2021) -
Paraspeckles modulate the intranuclear distribution of paraspeckle-associated Ctn RNA
por: Anantharaman, Aparna, et al.
Publicado: (2016)